# XTX202 in Patients With Advanced Solid Tumors

> **NCT05052268** · PHASE1,PHASE2 · COMPLETED · sponsor: **Xilio Development, Inc.** · enrollment: 95 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** XTX202

## Key facts

- **NCT ID:** NCT05052268
- **Lead sponsor:** Xilio Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-18
- **Primary completion:** 2025-03-22
- **Final completion:** 2025-03-25
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052268, "XTX202 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05052268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*